亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Combination Therapy with Immune Checkpoint Inhibitors and Anti-Angiogenic Agents: Mechanisms, Clinical Applications, and Challenges

作者
Eunchan Jung
出处
期刊: 卷期号:: 435-450
标识
DOI:10.70251/hyjr2348.44435450
摘要

Combination therapy with immune checkpoint inhibitors (ICIs) and anti-angiogenic agents has recently been an important therapeutic strategy in cancer treatment. This review discusses the mechanisms, clinical applications, limitations, and future research directions of this combination therapy. ICIs may restore exhausted T-cell activity and modify immune responses within the tumor microenvironment (TME), thereby contributing to tumor control in selected contexts. Anti-angiogenic agents target abnormal tumor angiogenesis, which can impair immune-cell infiltration and function and support tumor progression. By modulating vascular dysfunction and VEGF-mediated immunosuppression, anti-angiogenic therapy may enhance the activity of ICIs in certain tumor types, while ICI-induced immune activation may also influence vascular remodeling and antitumor immunity. Several ICI and anti-angiogenic agent combinations have been approved by the U.S. Food and Drug Administration (FDA) for selected malignancies and have demonstrated clinical benefit in specific patient populations. However, important questions remain regarding long-term efficacy, optimal dosing, treatment timing and sequencing, duration of therapy, immune-related adverse events, and tumor-specific resistance mechanisms. Responses may also differ across tumor types, drug classes, and tumor microenvironment states. Future research should focus on validating integrated biomarker strategies, improving toxicity prediction and management, clarifying resistance mechanisms, optimizing treatment sequencing, and extending follow-up to determine the durability of clinical benefit and safety. These efforts will be essential for improving the clinical use of combination therapy with ICIs and anti-angiogenic agents in appropriately selected patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
4秒前
6秒前
喻白完成签到,获得积分10
7秒前
萧雨墨发布了新的文献求助20
9秒前
喻白发布了新的文献求助10
9秒前
17秒前
Jun的应助被喻白采纳,获得10
19秒前
NexusExplorer的应助被LLL采纳,获得10
20秒前
24秒前
26秒前
30秒前
LLL完成签到,获得积分10
31秒前
fantasy的应助被科研通管家采纳,获得10
36秒前
36秒前
科研通AI65的应助被科研通管家采纳,获得10
36秒前
LLL发布了新的文献求助10
37秒前
榨菜完成签到 ,获得积分10
38秒前
CAOHOU的应助被萧雨墨采纳,获得10
53秒前
54秒前
yao发布了新的文献求助10
59秒前
七友完成签到 ,获得积分10
1分钟前
渢薃完成签到,获得积分10
1分钟前
踏实的初晴完成签到 ,获得积分10
1分钟前
1分钟前
充电宝的应助被白华苍松采纳,获得10
1分钟前
科研通AI6.3的应助被萧雨墨采纳,获得10
1分钟前
1分钟前
张宝完成签到,获得积分10
1分钟前
1分钟前
1分钟前
科研通AI65的应助被萧雨墨采纳,获得10
1分钟前
淡淡砖家完成签到,获得积分20
1分钟前
1分钟前
淡淡砖家发布了新的文献求助10
1分钟前
优雅柏柳发布了新的文献求助20
1分钟前
勤劳的星月完成签到,获得积分10
1分钟前
墨染完成签到 ,获得积分10
1分钟前
领导范儿的应助被淡淡砖家采纳,获得10
1分钟前
斯文败类的应助被萧雨墨采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190075
求助须知:如何正确求助?哪些是违规求助? 9577196
关于积分的说明 21851952
捐赠科研通 7788182
什么是DOI,文献DOI怎么找? 3436234
关于科研通互助平台的介绍 2559936
邀请新用户注册赠送积分活动 2482810